MA28821B1 - Procede pour ameliorer la biodisponibilite d'un inhibiteur de renine - Google Patents

Procede pour ameliorer la biodisponibilite d'un inhibiteur de renine

Info

Publication number
MA28821B1
MA28821B1 MA29709A MA29709A MA28821B1 MA 28821 B1 MA28821 B1 MA 28821B1 MA 29709 A MA29709 A MA 29709A MA 29709 A MA29709 A MA 29709A MA 28821 B1 MA28821 B1 MA 28821B1
Authority
MA
Morocco
Prior art keywords
biodisponibility
improving
renin inhibitor
renin
inhibitor
Prior art date
Application number
MA29709A
Other languages
English (en)
Inventor
Gian P Camenisch
Gerhard Gross
Isabel Ottinger
Daniel Wasmuth
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056890&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28821(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA28821B1 publication Critical patent/MA28821B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA29709A 2004-08-03 2007-02-22 Procede pour ameliorer la biodisponibilite d'un inhibiteur de renine MA28821B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59870004P 2004-08-03 2004-08-03

Publications (1)

Publication Number Publication Date
MA28821B1 true MA28821B1 (fr) 2007-08-01

Family

ID=35056890

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29709A MA28821B1 (fr) 2004-08-03 2007-02-22 Procede pour ameliorer la biodisponibilite d'un inhibiteur de renine

Country Status (31)

Country Link
US (1) US7709532B2 (fr)
EP (2) EP1776099B1 (fr)
JP (1) JP5134366B2 (fr)
KR (1) KR20070040384A (fr)
CN (1) CN1993116B (fr)
AR (1) AR050043A1 (fr)
AT (1) ATE449601T1 (fr)
AU (1) AU2005268844B2 (fr)
BR (1) BRPI0514021A (fr)
CA (1) CA2572743C (fr)
CY (1) CY1109826T1 (fr)
DE (1) DE602005017905D1 (fr)
DK (1) DK1776099T3 (fr)
EC (1) ECSP077169A (fr)
ES (1) ES2335597T3 (fr)
HR (1) HRP20100064T1 (fr)
IL (1) IL180678A (fr)
MA (1) MA28821B1 (fr)
MX (1) MX2007001339A (fr)
MY (1) MY142180A (fr)
NO (1) NO20071142L (fr)
NZ (1) NZ552903A (fr)
PE (1) PE20060416A1 (fr)
PL (1) PL1776099T3 (fr)
PT (1) PT1776099E (fr)
RU (1) RU2404758C2 (fr)
SI (1) SI1776099T1 (fr)
TN (1) TNSN07038A1 (fr)
TW (1) TW200616610A (fr)
WO (1) WO2006013094A1 (fr)
ZA (1) ZA200610639B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1891937A1 (fr) * 2006-08-25 2008-02-27 Novartis AG Formulations galéniques de l'aliskiren
EP1927350A1 (fr) * 2006-11-24 2008-06-04 Novartis AG Procéde pour améliorer la biodisponibilite d'un inhibiteur de renine
CA2769392A1 (fr) 2009-07-31 2011-02-03 Sandoz Ag Procede de preparation de ?o-amino-alcaneamides et o-amino-alcanethioamides
WO2012010651A2 (fr) 2010-07-23 2012-01-26 Sandoz Ag Procédé de préparation d'oméga-amino-alcaneamides et d'oméga-amino-alcanethioamides et intermédiaires de ce procédé
WO2014168255A1 (fr) * 2013-04-12 2014-10-16 国立大学法人京都大学 Accélérateur de la maturation de mégacaryocytes
WO2015035218A1 (fr) * 2013-09-05 2015-03-12 Howard University Procédé renforçant la biodisponibilité d'un médicament anti-vih
JP6029621B2 (ja) * 2014-07-14 2016-11-24 ヤマサ醤油株式会社 血漿レニン活性の測定法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108499A (en) 1993-02-04 2000-02-29 Lilly Co Eli Mammalian influx peptide transporter
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
CA2224227A1 (fr) 1995-06-07 1996-12-19 Avmax, Inc. Utilisation d'huiles essentielles pour accroitre la biodisponibilite des composes pharmaceutiques oraux
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CN1143680C (zh) * 1997-08-14 2004-03-31 阿旺蒂斯制药公司 增强非索非那定及其衍生物之生物利用度的方法
JP2003512443A (ja) * 1999-10-27 2003-04-02 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド タキサンをヒト患者に経口投与するための方法及び組成物
AU3808801A (en) * 2000-02-11 2001-08-20 Praecis Pharmaceuticals Incorporated Methods for enhancing the bioavailability of a drug
WO2001092468A2 (fr) * 2000-05-31 2001-12-06 Rutgers, The State University Of New Jersey Nouvelles compositions pour l'expression du transporteur 1 d'histidine de peptide humain et leurs procedes d'utilisation
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
GB0113663D0 (en) * 2001-06-05 2001-07-25 Novartis Ag Use of organic compounds
KR20040066177A (ko) 2001-12-19 2004-07-23 알자 코포레이션 친수성 거대분자의 경구 생체이용률을 증가시키기 위한제형 및 투여 형태
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
EP1501546B1 (fr) * 2002-05-03 2012-10-10 Hexal AG Formulation pharmaceutique stable contenant une statine combinee avec un inhibiteur de l'ace
PT1517682E (pt) * 2002-06-28 2007-02-28 Speedel Pharma Ag Formulação farmacêutica compreendendo inibidor da renina não-peptídico e tensioactivo
NZ549535A (en) * 2004-03-17 2010-11-26 Novartis Ag Use of aliskiren for treating renal and other disorders

Also Published As

Publication number Publication date
CN1993116B (zh) 2011-04-13
JP2008508340A (ja) 2008-03-21
US20080108703A1 (en) 2008-05-08
MY142180A (en) 2010-10-15
AR050043A1 (es) 2006-09-20
DK1776099T3 (da) 2010-03-01
KR20070040384A (ko) 2007-04-16
ZA200610639B (en) 2008-05-28
ECSP077169A (es) 2007-02-28
PL1776099T3 (pl) 2010-05-31
CN1993116A (zh) 2007-07-04
IL180678A0 (en) 2008-03-20
RU2404758C2 (ru) 2010-11-27
US7709532B2 (en) 2010-05-04
MX2007001339A (es) 2007-03-27
HRP20100064T1 (hr) 2010-03-31
EP1776099B1 (fr) 2009-11-25
ATE449601T1 (de) 2009-12-15
DE602005017905D1 (de) 2010-01-07
TNSN07038A1 (en) 2008-06-02
PT1776099E (pt) 2010-01-06
AU2005268844A1 (en) 2006-02-09
CA2572743A1 (fr) 2006-02-09
JP5134366B2 (ja) 2013-01-30
IL180678A (en) 2011-04-28
CA2572743C (fr) 2012-12-04
WO2006013094A1 (fr) 2006-02-09
RU2007107850A (ru) 2008-09-10
EP1776099A1 (fr) 2007-04-25
CY1109826T1 (el) 2014-09-10
SI1776099T1 (sl) 2010-03-31
AU2005268844B2 (en) 2009-03-05
ES2335597T3 (es) 2010-03-30
NZ552903A (en) 2010-09-30
TW200616610A (en) 2006-06-01
EP2191823A1 (fr) 2010-06-02
PE20060416A1 (es) 2006-06-09
NO20071142L (no) 2007-04-26
BRPI0514021A (pt) 2008-05-27

Similar Documents

Publication Publication Date Title
EP1676229A4 (fr) Procede pour creer un forfait d'abonnements
EP1734986A4 (fr) Procede pour la modulation de l'appetit
EP1925941A4 (fr) Procédé de prédiction de l'efficacité d'un inhibiteur de vascularisation
EP1991350A4 (fr) Procede pour augmenter la selectivite d'un catalyseur
FR2865731B1 (fr) Procede de fabrication d'un hydrofluoroalcane
EP1767528A4 (fr) Procede pour la production d'un compose 5-hydroxy-4-thiomethylpyrazole
MA28821B1 (fr) Procede pour ameliorer la biodisponibilite d'un inhibiteur de renine
EP1868953A4 (fr) Composition et procede de polissage d'une surface de saphir
EP1781420A4 (fr) Procede pour l'application d'une couche metallique decorative
EP1932952A4 (fr) Procédé de traitement de surface pour l'inhibition des barbes
FR2853919B1 (fr) Procede de fabrication d'un enrobe bitumineux
EP1961733A4 (fr) Procede pour produire selectivement un compose d'amine primaire
EP1995347A4 (fr) Procede de formation d'un film metallique
EP1743953A4 (fr) Procede de formation d'un film de cuivre
FR2897863B1 (fr) Procede d'hydrofugation d'un produit a base de gypse forme a partir d'une composition a base de platre
FR2846977B1 (fr) Procede pour ameliorer la qualite de non tisses
EP1786023A4 (fr) Procede pour la fabrication d'un substrat simox
FR2894596B1 (fr) Procede d'autocalibration de biopuces
FR2867077B1 (fr) Procede pour reduire les proprietes de contamination d'une surface par des microorganismes
EP1669461A4 (fr) Procede pour produire un cmp-acide n-acetyl-neuraminique
FR2882997B1 (fr) Procede d'exfoliation d'argiles intercalees
FR2868417B1 (fr) Procede de formation d'une liaison carbone-carbone
EP1756301A4 (fr) Procede destine a reguler la progression d'un cancer
EP1970947A4 (fr) MÉTHODE DE FORMATION D'UN FILM DE Cu
FR2843913B1 (fr) Procede pour realiser un decor